You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection
SBC: MKS Technology Topic: NIDADESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Reduced gluten cereal grains
SBC: Arcadia Biosciences, Inc. Topic: 300DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
SBC: FasCure Therapeutics LLC Topic: NIAIDDESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Synactix Pharmaceuticals I-Corps Application
SBC: SYNACTIX PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.
SBC: PROMUTECH PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory
SBC: Botanisol LLC Topic: RDESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder
SBC: Biomedical Development Corporation Topic: 103DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health